home / stock / tnya / tnya news

TNYA News and Press, Tenaya Therapeutics Inc. From 01/03/24

Stock Information
Company Name: Tenaya Therapeutics Inc.
Stock Symbol: TNYA
Market: NASDAQ
Menu
TNYA TNYA Quote TNYA Short TNYA News TNYA Articles TNYA Message Board
Get TNYA Alerts

News, Short Squeeze, Breakout and More Instantly...
TNYA - Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that ...
TNYA - Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that ...

TNYA - Expected earnings - Tenaya Therapeutics Inc.

Tenaya Therapeutics Inc. (TNYA) is expected to report $-0.47 for Q3 2023

TNYA - Tenaya Therapeutics GAAP EPS of -$0.39 beats by $0.09

2023-11-08 17:43:58 ET More on Tenaya Therapeutics Seeking Alpha’s Quant Rating on Tenaya Therapeutics Historical earnings data for Tenaya Therapeutics Financial information for Tenaya Therapeutics For further details see: Tenaya Therapeutics GAAP ...
TNYA - Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Commenced Patient Dosing in MyPeak-1 TM Phase 1b Trial of TN-201 in MYBPC3-Associated Hypertrophic Cardiomyopathy Presented Positive Phase 1 Data for TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at HFSA 2023 TN-401 for PKP2-A...

TNYA - Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

PKP2 Mutations Are the Leading Cause of ARVC, a Dangerous Condition Linked to Sudden Cardiac Arrest in Young People Estimated to Affect 70,000 People in the US TN-401 Preclinical Studies Demonstrated Robust Reduction of Ventricular Arrhythmias and Extended Survival in Knockout Models of...

TNYA - Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants Combination of Tenaya’s HDAC6 inhibitors with Empagliflozin Shows Additive Benefits in Preclinical HFpEF Model and High...
TNYA - PHG, GRTS and NVNO are among health care movers

2023-10-06 10:35:53 ET More on Health Care  Sector SPDR September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Citi turns cautious on pharmaceuticals and biotech BofA Securities: ...

TNYA - Tenaya Therapeutics Doses First Patient in the MyPeak-1(TM) Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that ...

TNYA - Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the p...
Previous 10 Next 10